MOTHER'S DAY SPECIALS! SHOW ME MORE

Close Notification

Your cart does not contain any items

$301.95

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
24 January 2025
Advances in Protein Chemistry and Structural Biology, Volume 143 in the series, covers reviews of methodology and research in all aspects of protein chemistry, including purification/expression, proteomics, modeling and structural determination and design. Chapters in this new release include Therapeutic insight into the role of nuclear protein HNF4α in liver carcinogenesis, Structural mechanism of nucleoporins in cancer disease, Identification of nuclear matrix proteins (novel genes) in bladder cancer using Bioinformatic approaches, A comparative study of nuclear proteins of different cancers - A systematic review, Role of lamins in cellular physiology and cancer, and much more.

Other chapters cover Nuclear Hormone Receptors as Drug Targets: Advancements and Future Prospects, Proteins binding to tandemly repeated DNA: familiar strangers, HMGB1, R-loops and genome stability, Nuclear tau accumulation in Alzheimer's Disease, and Histone deacetylase's (HDACs) regulates Tau function in Alzheimer's Disease.
Series edited by:  
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 229mm,  Width: 152mm, 
Weight:   450g
ISBN:   9780443295645
ISBN 10:   0443295646
Series:   Advances in Protein Chemistry and Structural Biology
Pages:   444
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active
1. Therapeutic insight into the role of nuclear protein HNF4a in liver carcinogenesis Ramanathan Gnanasambandan Sr. 2. Structural Mechanism of Nucleoporins in Cancer Disease Selvaraj Chandrabose Sr. 3. Identification of nuclear matrix proteins (novel genes) in bladder cancer using Bioinformatic approaches George Priya Doss C 4. A comparative study of nuclear proteins of different cancers - A systematic review George Priya Doss C 5. Role of Lamins in Cellular Physiology and Cancer Ajaz Ahmad Bhat 6. Pushing the envelope - how the genome interacts with the nuclear envelope in health and disease Joanna Bridger 7. Identification of mutations and function analysis of nuclear proteins using bioinformatic approaches George Priya Doss C 8. uclear Hormone Receptors as Drug Targets: Advancements and Future Prospects Dileep Francis 9. Proteins binding to tandemly repeated DNA: familiar strangers Olga Podgornaya and Natella Enukashvily 10. HMGB1 Iva Ugrinova 11. R-loops and genome stability Anastas Gospodinov 12. TBC Vikas Rishi 13. TBC Pedro A Lazo 14. Nuclear Tau accumulation in Alzheimer's Disease Subashchandrabose Chinnathambi 15. Histone Deacetylase's (HDACs) regulates Tau function in Alzheimer's Disease Subashchandrabose Chinnathambi

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

See Also